<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00562510</url>
  </required_header>
  <id_info>
    <org_study_id>FH-RAL-01</org_study_id>
    <secondary_id>ANMAT-1-4721846/07-6</secondary_id>
    <nct_id>NCT00562510</nct_id>
  </id_info>
  <brief_title>Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery</brief_title>
  <official_title>A Phase 3, Randomized, Double Blinded, Placebo Controlled Study of Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pedro Cahn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Huésped</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, randomized, double blinded, placebo-controlled study designed to compare&#xD;
      the safety, tolerability, antiviral activity and immunological effect of raltegravir added to&#xD;
      a previously stable HAART regimen in the treatment of HIV-1 infected subjects with&#xD;
      undetectable viraemia and low CD4 recovery.&#xD;
&#xD;
      HYPOTHESIS:&#xD;
&#xD;
      Adding raltegravir to a stable HAART in patients with undetectable plasma viral load and low&#xD;
      CD4 recovery will result in further viral suppression and therefore higher CD4 recovery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although HAART has reduced the morbidity and mortality from HIV-1 infection, some patients&#xD;
      experience a discordant response characterized by HIV-1 RNA plasma levels below the limit of&#xD;
      detection and low CD4 T-cell recovery (immunologic discordant responders). At present,&#xD;
      recommendations for the clinical management of patients with discordant responses to&#xD;
      antiretroviral therapy are largely based on observational, uncontrolled data.&#xD;
&#xD;
      The effect on CD4 count of adding raltegravir in already undetectable patients has not yet&#xD;
      been evaluated.&#xD;
&#xD;
      The primary purpose of this study is to assess the ability of the HIV-1 integrase inhibitor,&#xD;
      raltegravir, added to a stable HAART, to increase CD4 count in patients with undetectable&#xD;
      plasma viral load and low CD4 recovery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruitment lower than estimated&#xD;
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects increasing CD4 count &gt; 50 cells/mm³.</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving plasma HIV-RNA &lt; 5 copies/ml.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects increasing CD4 count &gt; 50 cells/mm³.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving CD4 count &gt; 250 cells/mm3</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving an increase of 5 percentual points in CD4 percentage</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median change from baseline in CD4 count.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients maintaining HIV RNA &lt;50 copies/ml.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Raltegravir matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Raltegravir 400 mg BID added to stable HAART</description>
    <arm_group_label>Raltegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo BID added to stable HAART</description>
    <arm_group_label>Raltegravir matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented HIV-1 infection.&#xD;
&#xD;
          -  Subject has voluntarily signed and dated an informed consent form.&#xD;
&#xD;
          -  Documented sustained HIV RNA &lt; 50 copies/ml (two consecutive pVL &lt; 50 copies/ml, first&#xD;
             VL &gt; 12 months before the screening date) without documentation of HIV RNA &gt; 50&#xD;
             copies/ml for at least 12 months while on previous stable HAART (PS_HAART).&#xD;
&#xD;
          -  HIV RNA &lt; 50 copies/ml at screening.&#xD;
&#xD;
          -  Subject is currently receiving an antiretroviral regimen which has not changed for at&#xD;
             least 12 months.&#xD;
&#xD;
          -  CD4 count &lt; 200 cells/ mm3 AND CD4 increase &lt; 100 cells/ mm3 in the last 12 months.&#xD;
&#xD;
          -  Subject's vital signs, physical examination and laboratory results do not exhibit&#xD;
             evidence of acute illness.&#xD;
&#xD;
          -  Negative serum or urine pregnancy test and willing to use acceptable means of&#xD;
             contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is receiving tenofovir DF AND didanosine as a component of the background&#xD;
             antiretroviral therapy.&#xD;
&#xD;
          -  Patient has a current (active) diagnosis of acute hepatitis due to any cause OR&#xD;
             chronic hepatitis B and/or C WITH aspartate aminotransferase (AST) and/or alanine&#xD;
             aminotransferase (ALT)&gt;2.5 x upper limit of normal (ULN) AND/OR is likely to require&#xD;
             treatment in the next year.&#xD;
&#xD;
          -  Subject has significant history of cardiac, renal, neurologic, psychiatric, oncologic,&#xD;
             metabolic, or hepatic disease or any condition that, in the investigators opinion,&#xD;
             could compromise the subject's safety or adherence to the trial protocol.&#xD;
&#xD;
          -  Subject has a currently active AIDS defining illness (category C conditions according&#xD;
             to the CDC Classification System for HIV infection 1993) within 30 days of screening.&#xD;
             Subjects who are on stable maintenance therapy for an opportunistic infection may be&#xD;
             enrolled.&#xD;
&#xD;
          -  Life expectancy &lt; 1 year according to the judgment of the investigator.&#xD;
&#xD;
          -  Screening laboratory analysis show any of the following abnormal laboratory results:&#xD;
&#xD;
               -  Hemoglobin &lt; 8.0 g/dL&#xD;
&#xD;
               -  Absolute neutrophil count &lt; 750 cells/µL&#xD;
&#xD;
               -  Platelet count &lt; 50,000 mm3&#xD;
&#xD;
          -  Use of any investigational agents within 30 days prior to screening.&#xD;
&#xD;
          -  Previous use of integrase inhibitors.&#xD;
&#xD;
          -  Use of immunosuppressive drugs, cytokine inhibitors or other cytokines in the last&#xD;
             year.&#xD;
&#xD;
          -  Continuous use of systemic corticoids for more than a month in the last year or any&#xD;
             use in the last 3 months.&#xD;
&#xD;
          -  Subject has an ongoing history of substance abuse or psychiatric illness.&#xD;
&#xD;
          -  Subject is pregnant or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro E Cahn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion Huesped</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundacion Huesped</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1202</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <link>
    <url>http://www.huesped.org.ar</url>
    <description>Fundacion Huesped</description>
  </link>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2007</study_first_posted>
  <last_update_submitted>June 5, 2015</last_update_submitted>
  <last_update_submitted_qc>June 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Huésped</investigator_affiliation>
    <investigator_full_name>Pedro Cahn</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>HIV-1 infection</keyword>
  <keyword>raltegravir</keyword>
  <keyword>immune discordance</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

